Skip to content
CancerIndex

Publication

The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.

Authors not recorded

Am J Cancer Res2016PMID 27904766PMC5126268stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (6)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 6

Curated evidence

Evidence citing this paper (3)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
27904766
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
PIM1 L2V1
IbrutinibDiffuse Large B-Cell Lymphoma Activated B-Cell TypePredictiveDSupports Resistance3accepted
EID9945

Foundation panel results of baseline tumour samples from 48 patients with diffuse large B cell lymphoma identified PIM1 mutations in 6 patient samples, 5 of which were the DLBCL-ABC subtype. Four out … (full text at CIViC)

PMID 27904766 · Kuo et al., 2016 · Open in CIViC

civic
PIM1 P81S1
IbrutinibDiffuse Large B-Cell Lymphoma Activated B-Cell TypePredictiveDSupports Resistance3accepted
EID9946

Foundation panel results of baseline tumour samples from 48 patients with diffuse large B cell lymphoma identified PIM1 mutations in 6 patient samples, 5 of which were the DLBCL-ABC subtype. Four out … (full text at CIViC)

PMID 27904766 · Kuo et al., 2016 · Open in CIViC

civic
PIM1 S97N1
IbrutinibDiffuse Large B-Cell Lymphoma Activated B-Cell TypePredictiveDSupports Resistance3accepted
EID9947

Foundation panel results of baseline tumour samples from 48 patients with diffuse large B cell lymphoma identified PIM1 mutations in 6 patient samples, 5 of which were the DLBCL-ABC subtype. Four out … (full text at CIViC)

PMID 27904766 · Kuo et al., 2016 · Open in CIViC

civic